Van Straalen K.R., Tzellos T., Alavi A., Benhadou F., Cuenca-Barrales C., Daxhelet M., Daoud M., Efthymiou O., Giamarellos-Bourboulis E.J., Guillem P., Gulliver W., Jemec G.B.E., Katoulis A., Koenig A., Lazaridou E., Lowes M.A., Marzano A.V., Matusiak L., Molina-Leyva A., Moltrasio C., Pinter A., Potenza C., Prens E.P., Romaní J., Saunte D.M., Sayed C., Skroza N., Stergianou D., Szepietowski J.C., Trigoni A., Vilarrasa E., Kyrgidis A., Zouboulis C.C., Van Der Zee H.H.. External Validation of the IHS4-55 in a European Antibiotic-Treated Hidradenitis Suppurativa Cohort. DERMATOLOGY. 2023; 239(3)DOI:10.1159/000528968. PMID:36630943. IF:3.000(Q2/4D).

Pereira M.P., Weisshaar E., Halvorsen J.A., Wallengren J., Legat F.J., Garcovich S., Savk E., Reich A., Bozek A., Lvov A., Bobko S., Metz M., Streit M., Misery L., Brenaut E., Serra-Baldrich E., Gonçalo M., Szepietowski J.C., Augustin M., Nau T., Zeidler C., Ständer S.. Chronic prurigo: Insufficient disease control in spite of high healthcare usage. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; 37(6)DOI:10.1111/jdv.18903. PMID:36682045. IF:8.500(Q1/1D).

Blauvelt A., Thyssen J.P., Guttman-Yassky E., Bieber T., Serra-Baldrich E., Simpson E., Rosmarin D., Elmaraghy H., Meskimen E., Natalie C.R., Liu Z., Xu C., Pierce E., Morgan-Cox M., Garcia Gil E., Silverberg J.I.. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. BRITISH JOURNAL OF DERMATOLOGY. 2023; 188(6)DOI:10.1093/bjd/ljad022. PMID:36994947. IF:11.000(Q1/1D).

Carrascosa J.M., Vilarrasa E., Belinchón I., Herranz P., Crespo J., Guimerá F., Olveira A.. [Translated article] Common Approach to Metabolic-Associated Fatty Liver Disease in Patients With Psoriasis: Consensus-Based Recommendations From a Multidisciplinary Group of Experts [Abordaje común del paciente con psoriasis y riesgo de esteatosis hepática metabólica: recomendaciones de un grupo de expertos multidisciplinar]. Actas Dermo-Sifiliograficas. 2023; 114(5)DOI:10.1016/j.ad.2023.04.013. PMID:37068635. IF:(Q/D).

Schneller-Pavelescu L., Vergara-de Caso E., Martorell A., Romaní J., Lázaro M., Vilarrasa E., Díaz-Ley B., Vázquez-Osorio I., Segura Palacios J.M., Azaña J.M., González-López M.A., Cañueto J., Molina-Leyva A., Leiva-Salinas M., Navarro-Triviño F.J., Sánchez-Payá J., Pascual J.C.. Reply to: “Comment on ‘Interruption of oral clindamycin plus rifampicin therapy in patients with hidradenitis suppurativa: An observational study to assess prevalence and causes’”. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2023; 88(5)DOI:10.1016/j.jaad.2019.03.006. PMID:30872153. IF:12.800(Q1/1D).

Yélamos O., Geller S., Tokez S.. Skin cancer special issue in Skin Health and Disease. Skin Health And Disease. 2023; 3(2)DOI:10.1002/ski2.224. PMID:37013119. IF:(Q/D).